<- Go Home
RHS Limited
RHS Limited develops and markets biotechnology solutions. It offers EmbryoCellect, a preimplantation genetic screening solution; DOPlify, a whole genome amplification kit; and PG-Seq, a NGS workflow solution for preimplantation genetic testing for aneuploidy and preimplantation genetic testing for monogenic disorders. The company also provides preimplantation genetic screening and whole genome amplification services. RHS Limited was formerly known as Reproductive Health Science Limited and changed its name to RHS Limited in June 2017. The company was founded in 1980 and is based in Thebarton, Australia. As of June 14, 2018, RHS Limited operates as a subsidiary of Revvity, Inc.
Market Cap
AUD 24.7M
Volume
291.6K
Cash and Equivalents
AUD 852.6K
EBITDA
-AUD 2.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
AUD 131.1K
Profit Margin
62.27%
52 Week High
AUD 0.28
52 Week Low
AUD 0.10
Dividend
N/A
Price / Book Value
36.06
Price / Earnings
-11.80
Price / Tangible Book Value
38.97
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-AUD 2.0M
Return on Equity
207.10%
Return on Assets
-82.60
Cash and Short Term Investments
AUD 852.6K
Debt
AUD 118.9K
Equity
AUD 685.9K
Revenue
AUD 210.5K
Unlevered FCF
-AUD 1.2M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium